Nice

• A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients … Ended recruitment
  2023-507130-24-00 5 2021-10-22 Neovascular age-related macular degeneration (nAMD)
• CORTICOP_Comparison of corticosteroids versus placebo on duration of ventilatory support during severe acute exacerbations of COPD patients … Ended recruitment
  2024-516651-41-00 5 2021-10-08 COPD : chronic obstructive Pulmonary disease
• Long-term safety of apraglutide in short bowel syndrome Ended recruitment
  2023-510389-28-00 5 2021-06-14 short bowel syndrome
• A Phase 1b/2 Study of BMS-986158 Monotherapy and Combination with either Ruxolitinib or Fedratinib in Intermediate or High Risk Myelofibrosi … Ended recruitment
  2023-509635-89-00 9 2021-06-01 DIPSS-Intermediate or High Risk Myelofibrosis
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended recruitment
  2023-507132-21-00 10 2021-05-11 Early Parkinson's disease
• Study to evaluate the efficacy and safety of MAS825 in patients with autoinflammatory diseases. Ended recruitment
  2023-504419-34-00 4 2021-04-29 Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also
• A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended recruitment
  2023-509120-17-00 5 2021-04-12 Myelofibrosis
• A Study of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Ac … Ended recruitment
  2024-514467-26-00 4 2021-04-07 Indolent Systemic Mastocytosis
• Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing c … Ended recruitment
  2024-511658-28-01 5 2021-04-06 primary sclerosing cholangitis
• Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended recruitment
  2023-506962-30-00 5 2021-03-29 Non-alcoholic steatohepatitis (NASH)
• Inebilizumab efficacy and safety in adults with myasthenia gravis Ended recruitment
  2023-510006-40-00 5 2021-03-22 Myasthenia Gravis which is either due to acetylcholine receptor antibo
• A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended recruitment
  2023-507890-17-00 5 2021-02-22 Anemia associated with myeloproliferative neoplasm (MPN)-associated my
• FIBRAPLO - Haplo-identical transplantation in patients with myleofibrosis Ended recruitment
  2024-513325-23-00 4 2021-02-03 Myelofibrosis
• A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended recruitment
  2024-514502-31-00 5 2021-01-11 Prurigo Nodularis
• A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended recruitment
  2022-501645-70-00 5 2020-11-25 Crohns Disease
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc … Ended recruitment
  2022-502611-10-00 5 2020-11-24 Primary Progressive Multiple Sclerosis (PPMS)
• Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk … Ended recruitment
  2023-507153-16-00 5 2020-11-18 Higher-Risk Myelodysplastic Syndrome
• The USTAP CD trial USTekinumab in fistulising Perianal Crohn’s Disease: The USTAP CD study Ended recruitment
  2023-503380-42-00 6 2020-11-16 patient with moderate to severe Crohn's disease with at least one acti
• A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects with Advanced C … Ended recruitment
  2024-517536-22-00 7 2020-09-22 Unresectable or metastatic cutaneous squamous cell carcinoma
• Rituximab from the first episode of Minimal Change Nephrotic Syndrome for preventing relapse risk in adult patients Ended recruitment
  2024-516102-36-00 4 2020-07-29 Minimal Change Nephrotic Syndrom
• A Phase 3 study to compare long-term efficacy and safety of macitentan 75 mg versus 10 mg in Pulmonary Arterial Hypertension. Ended recruitment
  2024-515669-32-00 5 2020-06-30 Pulmonary arterial hypertension
• A study to evaluate if benralizumab may be beneficial in the treatment of Hypereosinophilic Syndrome (HES). Ended recruitment
  2023-510455-28-00 5 2020-06-10 Hypereosinophilic Syndrome (HES)
• Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Ended recruitment
  2024-511653-22-00 5 2020-02-12 Cutaneous Squamous Cell Carcinoma (CSCC)
• A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral trea … Ended recruitment
  2024-511940-20-00 5 2020-02-05 Parkinson's disease

Showing 481–504 of 672 trials